Inogen (INGN) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" INGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares.
View INGN analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 12-month price objectives for Inogen's shares. Their INGN share price forecasts range from $22.00 to $26.00. On average, they predict the company's stock price to reach $24.00 in the next year. This suggests a possible upside of 115.1% from the stock's current price.
View analysts price targets for INGN or view top-rated stocks among Wall Street analysts.

Inogen's stock was trading at $19.71 on January 1st, 2023. Since then, INGN shares have decreased by 43.4% and is now trading at $11.16.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our INGN earnings forecast.

Inogen, Inc. (NASDAQ:INGN) released its quarterly earnings data on Thursday, May, 4th. The medical technology company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.14. The medical technology company earned $72.16 million during the quarter, compared to the consensus estimate of $74.68 million. Inogen had a negative net margin of 24.36% and a negative trailing twelve-month return on equity of 11.06%. The company's quarterly revenue was down 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.38) earnings per share.

ETFs with the largest weight of Inogen (NASDAQ:INGN) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Cultivar ETF (CVAR), Syntax Stratified SmallCap ETF (SSLY), Invesco S&P SmallCap Health Care ETF (PSCH), Principal Healthcare Innovators ETF (BTEC), iShares U.S. Medical Devices ETF (IHI),

70 employees have rated Inogen Chief Executive Officer Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among the company's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Inogen's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (17.20%), Brown Capital Management LLC (9.55%), Fred Alger Management LLC (4.86%), State Street Corp (4.65%), Dimensional Fund Advisors LP (3.72%) and Geode Capital Management LLC (1.95%). Insiders that own company stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Holdings A/S Novo, Ray Benjamin M Anderson and Raymond Huggenberger.
View institutional ownership trends.

Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INGN stock can currently be purchased for approximately $11.16.

Inogen (NASDAQ:INGN) has a market capitalization of $258.03 million and generates $369.02 million in revenue each year. The medical technology company earns $-83,770,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis.

The company employs 1,026 workers across the globe.

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The official website for the company is www.inogen.com. The medical technology company can be reached via phone at (805) 562-0500 or via email at mpigeon@inogen.net.